<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">A1 Reactive Astrocytes</th>
</tr>
<tr>
<td class="label">Lineage</td>
<td>Glia > Astrocyte > Reactive > A1</td>
</tr>
<tr>
<td class="label">Markers</td>
<td>C3, Serping1, Gsr, Fbln5, complement components</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>Hippocampus, Cortex, Substantia Nigra, Motor Cortex</td>
</tr>
<tr>
<td class="label">Inducer</td>
<td>Microglia (IL-1α, TNF, C1q)</td>
</tr>
</table>
<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">A1 Reactive Astrocytes</th>
</tr>
<tr>
<td class="label">Lineage</td>
<td>Glia > Astrocyte > Reactive > A1</td>
</tr>
<tr>
<td class="label">Markers</td>
<td>C3, Serping1, Gsr, Fbln5, complement components</td>
</tr>
<tr>
<td class="label">Brain Regions</td>
<td>Hippocampus, Cortex, Substantia Nigra, Motor Cortex</td>
</tr>
<tr>
<td class="label">Inducer</td>
<td>Microglia (IL-1α, TNF, C1q)</td>
</tr>
</table>
A1 reactive astrocytes are a toxic subtype of reactive astrocytes identified in neurodegenerative conditions. They adopt a destructive phenotype driven by microglial signaling and actively contribute to neuronal and synaptic loss. The discovery of A1 astrocytes in 2017 by Liddelow et al. represented a paradigm shift in our understanding of astrocyte biology in neurodegeneration, revealing that not all reactive astrocytes are beneficial["@liddelow2017"].
A1 reactive astrocytes were first characterized through single-cell RNA sequencing of mouse models of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease), and amyotrophic lateral sclerosis (ALS). These astrocytes are induced by microglial release of pro-inflammatory cytokines (IL-1α, TNF, and C1q) and adopt a phenotype that is toxic to [neurons](/entities/neurons) and synapses[@guttenplan2020].
The A1 phenotype contrasts with the A2 reactive astrocytes, which appear to be neuroprotective and are primarily induced by ischemia and stroke. Understanding the balance between A1 and A2 astrocytes has important implications for developing therapies targeting astrocyte-mediated neuroinflammation.
The landmark 2017 study by Liddelow et al. used single-cell RNA sequencing to profile astrocytes in multiple mouse models of neurodegeneration. Key findings included:
A1 astrocytes are induced by activated [microglia](/entities/microglia) through the release of three key molecules:
The induction of A1 astrocytes involves several intracellular signaling pathways:
| Gene | Function |
|------|----------|
| C3 | Complement component 3 - the hallmark A1 marker |
| Serping1 | Serpin peptidase inhibitor |
| Gsr | Glutathione reductase |
| Fbln5 | Fibulin-5 |
| C4b | Complement component |
| H2-D1 | MHC class I molecule |
| Gene | Function |
|------|----------|
| GLT-1 (SLC1A2) | Major glutamate transporter |
| Aqp4 | Aquaporin-4 water channel |
| Kir4.1 (KCNJ10) | Potassium channel |
| SLC39A12 | Zinc transporter |
The downregulation of glutamate transporters and potassium channels is particularly significant for neuronal health, as it impairs astrocytic buffering of the extracellular environment.
A1 astrocytes actively phagocytose synapses through:
A1 astrocytes are directly toxic to neurons through:
A1 astrocytes are prominently found in AD brain tissue:
In PD, A1 astrocytes contribute to dopaminergic neuron loss:
A1 astrocytes are particularly prominent in ALS:
| Strategy | Approach | Status |
|----------|----------|--------|
| IL-1α blockade | Anakinra (IL-1 receptor antagonist) | Preclinical |
| Complement inhibition | Anti-C1q, anti-C3 antibodies | In development |
| Microglial modulation | CSF1R inhibitors | Clinical trials |
| A1 to A2 conversion | Unknown factors needed | Research stage |
C3 and other A1 markers in cerebrospinal fluid may serve as:
The study of A1 Reactive [Astrocytes](/entities/astrocytes) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
A1 astrocytes are characterized by a distinct transcriptional signature:
The following diagram shows the key molecular relationships involving A1 Reactive Astrocytes discovered through SciDEX knowledge graph analysis: